Cidara Therapeutics, Inc.
CDTX
$220.98
$1.090.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 43.16% | 0.88% | |||
| Gross Profit | -43.16% | -0.88% | |||
| SG&A Expenses | 24.56% | 5.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.30% | 23.94% | |||
| Operating Income | -39.30% | -23.94% | |||
| Income Before Tax | -223.64% | -9.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -223.64% | -9.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -223.64% | -9.53% | |||
| EBIT | -39.30% | -23.94% | |||
| EBITDA | -39.33% | -24.01% | |||
| EPS Basic | -87.17% | 0.11% | |||
| Normalized Basic EPS | 25.43% | -15.16% | |||
| EPS Diluted | -87.17% | 0.11% | |||
| Normalized Diluted EPS | 25.43% | -15.16% | |||
| Average Basic Shares Outstanding | 72.91% | 9.66% | |||
| Average Diluted Shares Outstanding | 72.91% | 9.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||